Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV). Founded in 2014, the company's headquarters are located in Sioux Falls, South Dakota, with a secondary office situated in Cambridge, Massachusetts.